On October 31, 2023 Capstan Therapeutics, Inc. ("Capstan"), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery utilizing targeted lipid nanoparticles (tLNP), reported that it will present preclinical data showing rapid and robust anti-tumor and anti-primary B cell activity in humanized mice by tLNP administration delivering an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR), at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting in San Diego, California (Press release, Capstan Therapeutics, OCT 31, 2023, View Source [SID1234636598]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"These data highlight the potential for Capstan’s targeted LNP-mRNA platform to provide a truly disruptive, off-the-shelf, cell-free, scalable and tunable solution for patients without the need for harsh lymphodepletion conditioning or viral vectors that are required for conventional ex vivo cell therapies," said Adrian Bot, M.D., Ph.D., Capstan’s Chief Scientific Officer, and Executive Vice President of R&D. "We have demonstrated efficient and therapeutically relevant delivery of mRNA CAR payloads to human T cells. This resulted in rapid and profound pharmacodynamic effect in two mouse models, comprising eradication of human primary B cells or Nalm6 leukemic cells, respectively. These data provide a springboard for developing novel, in vivo CAR therapies that may overcome access and clinical performance issues with currently available ex vivo CAR therapies, with broad applicability in autoimmune and oncology indications."
Poster Details:
Title: In vivo engineering of CAR T cells using a novel targeted LNP-mRNA technology
Presentation type: Poster
Session: Poster Hall
Date and time: Saturday, November 4, 2023: 9:00 AM – 8:30 PM
Lead authors: Gregor Adams, Ph.D., and Haig Aghajanian, Ph.D.
A copy of the poster will be added to the "Publications and News" section of Capstan’s website at www.capstantx.com/.